Back to results
US 2009/0291464 A1Published application
Methods for Measuring Affinity Substances in Samples Containing Blood Cell Components
OwnerKeisuke Iwatainventor
Life of this patent
Estimating the term…
Abstract
In the methods for measuring affinity substances using pearl chain formation of carrier particles, the use of carrier particles having a particular particle diameter enables carrier particles to be specifically counted even if blood cell components coexist. Whole blood samples can be used as samples to be measured without separating serum and plasma. Therefore, there is no need to separate serum or plasma when analyzing blood cell components.
Claims18
A method for measuring an affinity substance, which comprises the steps of (1) to (3) or (1′) to (3′):
- (1) applying a voltage pulse to a reaction solution in which a target affinity substance is mixed with carrier particles which are bound to a binding partner having an activity to bind to the target affinity substance;
- (2) counting either or both of agglutinates of carrier particles formed due to binding of the target affinity substance, and/or unagglutinated carrier particles which are not bound to the target affinity substance, based on their three-dimensional information as an indicator;
- and
- (3) determining the level of the target substance based on either or both of the level of agglutinate formation and/or the level of unagglutinated carrier particles;
- or
- (1′) applying a voltage pulse to a reaction solution in which an agglutination reagent component is mixed with a target affinity substance and carrier particles which are bound to a binding partner having an activity to bind to the target affinity substance, wherein the carrier particles agglutinate due to the agglutination reagent, and the agglutination is inhibited by the target affinity substance;
- (2′) counting either or both of agglutinates of carrier particles formed due to binding of the agglutination reagent, and/or carrier particles whose agglutination is inhibited by binding of the target affinity substance, based on their three-dimensional information as an indicator;
- and
- (3′) determining the level of the target substance based on either or both of the level of agglutinate formation and/or the level of unagglutinated carrier particles,
- wherein the target affinity substance is included in a medium comprising blood cell components,
- wherein step (1) or (1′) is carried out in the presence of said medium, and wherein the carrier particles in step (1) or (1′) are of a size that yields agglutinates having a volume that can be distinguished from blood cell components.
8 more elements
Dependencies are inferred from the claim text.